Compare Expedia Group Inc (EXPE) vs Summit Therapeutics Inc (SMMT) Price & Performance

Expedia Group (EXPE) trades at $274.22, up 5.93% over the past 24 hours, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows a bullish technical signal with key resistance at $275 and support at $264. Fundamentally, the company reported $14.73B in 2025 revenue with a net income margin of 12.97%, while recent news highlights AI-driven competitive pressures and strategic partnerships.

The outlook for EXPE is cautiously optimistic, with a consensus price target of $335.06 implying 22% upside. Key opportunities include robust travel demand and improving profitability, but risks involve AI disruption from Meta's Muse agent and heightened competition. Analyst sentiment is mixed, with 47% buy ratings versus 50% hold, signaling balanced but uncertain near-term prospects.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.